LifeSci Capital analyst Francois Brisebois reiterated a Buy rating on Dyne Therapeutics today and set a price target of $40.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Francois Brisebois has given his Buy rating due to a combination of factors including Dyne Therapeutics’ recent financial performance and promising developments in their clinical trials. The company reported a better-than-expected earnings per share for the third quarter of 2025, which was attributed to disciplined operational expenses. This financial performance, coupled with updates on their ACHIEVE trial in DM1 and DELIVER trial in DMD, suggests a positive outlook for the company’s future.
Furthermore, the expansion of trial sites, including new ones in the US, has led to a revised timeline for full enrollment in the ACHIEVE trial, now expected in early second quarter of 2026. This expansion is seen as a strategic move that could position Dyne Therapeutics to be first-to-market, assuming they receive Priority Review. The potential for accelerated approval in the US and the anticipated data from the DELIVER trial in December 2025 are additional factors supporting the Buy rating, as they indicate a strong potential for future growth and market presence.
In another report released today, Stifel Nicolaus also maintained a Buy rating on the stock with a $36.00 price target.